Introduction {#s1}
============

Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human tumors, with a five year survival rate below 10% ([@bib72]). Despite the overall association with poor clinical outcomes, a striking heterogeneity in the presentation and progression of this disease exists between individuals, including differing rates of metastatic spread and responses to cytotoxic chemotherapy ([@bib15]). Owing to this issue, a major objective in PDA research is to uncover molecular mechanisms that underpin this clinical heterogeneity. Such efforts may yield much-needed biomarkers capable of predicting disease progression, as well as personalized therapeutic strategies that target critical disease drivers in each patient's tumor.

It has long been recognized that a subset of pancreatic tumors exhibit an 'adenosquamous' histology, which is characterized by the presence of both glandular and squamous neoplastic cells within the same tumor ([@bib38]; [@bib52]; [@bib54]). The designation of adenosquamous pancreatic cancer as a disease entity has been reinforced by several recent transcriptome profiling studies of human pancreatic tumors, which identified aberrant expression of squamous (also known as basal) lineage markers in \~15% of samples, in association with exceptionally poor clinical outcomes ([@bib5]; [@bib11]; [@bib50]). While squamous cells are a normal cell type in several stratified epithelial tissues (e.g. in the skin and esophagus), they are not known to be present in the normal human pancreas ([@bib7]). This suggests an aberrant ductal-to-squamous epithelial cell fate transition is induced during pancreatic tumorigenesis.

The functional relevance of squamous trans-differentiation in pancreatic cancer was unclear until recently, when studies from several laboratories, including our own, demonstrated that the transcription factor p63 (ΔN isoform, hereafter referred to as p63 for simplicity) is the master regulator of the adenosquamous phenotype in PDA ([@bib4]; [@bib31]; [@bib73]). The p63 protein is encoded by the *TP63* gene in humans. Once expressed, p63 binds to thousands of genomic sites to nucleate the formation of active enhancers to drive expression of squamous lineage genes (e.g. *KRT5/6* and *S100A2*) in PDA cells ([@bib31]; [@bib73]). Importantly, p63 is both necessary and sufficient to endow PDA cells with the same squamous lineage transcriptional program that is observed in pancreatic tumors with adenosquamous histology ([@bib5]; [@bib31]; [@bib73]). While the mechanisms that induce p63 expression in PDA remain unclear, it has been shown in mice that inactivation of the tumor suppressor *Kdm6a* or over-expression of *Myc* can predispose pancreatic tumors to express squamous markers, albeit with partial penetrance ([@bib4]; [@bib33]; [@bib81]). In support of the functional impact of squamous trans-differentiation in PDA, induction of p63 leads to a collection of cell-autonomous phenotypic alterations, including enhanced motility, invasion, and resistance to cytotoxic chemotherapy ([@bib17]; [@bib73]).

Evidence from human patients and mouse models supports a powerful effect of inflammation in driving PDA progression ([@bib13]; [@bib30]; [@bib29]; [@bib84]). A key step in this process is an elaboration of pro-inflammatory cytokines by tumor cells and non-neoplastic cells in the stromal compartment ([@bib48]). For example, many pancreatic tumors are infiltrated with neutrophils, which suppress anti-tumor T-cell immunity in PDA mouse models and correlate with aggressive disease in humans ([@bib8]; [@bib12]; [@bib37]; [@bib70]; [@bib74]). A major cell type in the stroma of PDA tumors are CAFs, which have historically been considered tumor-promoting ([@bib57]), however recent studies suggest they may also have tumor-restraining functions ([@bib60]; [@bib67]). A subset of CAFs with myofibroblastic properties, termed myCAFs, appear to be involved in the production of extracellular matrix which may limit drug delivery to the tumor ([@bib59]; [@bib63]; [@bib71]). Another subset of CAFs, termed iCAFs, have low expression of myCAF markers and instead produce high levels of inflammatory cytokines and chemokines, such as IL-6, CXCL1, and LIF ([@bib58]). Although the iCAF/myCAF ratio, the extent of neutrophil infiltration, and the overall level of stromal inflammation can vary between PDA patients, the underlying features of cancer cells that drive these differences are only beginning to be understood ([@bib9]; [@bib75]; [@bib78]).

Here we provide evidence that p63-expressing squamous PDA cells have an enhanced capability to promote inflammatory changes within the tumor microenvironment when compared to p63-negative PDA cells. These findings are supported by in vitro and in vivo experiments, and include activation of an inflammatory transcriptional program in CAFs of the tumor stroma. These effects are mediated via a specific cytokine secretion phenotype of PDA cells downstream of p63-mediated enhancer reprogramming. Taken together, these findings illustrate how lineage alterations within cancer cells orchestrate non cell-autonomous changes in the tumor microenvironment.

Results {#s2}
=======

A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in vitro {#s2-1}
-------------------------------------------------------------------------------------------------------------------

In a prior study, we found that ectopic expression of p63 in the human PDA cell line SUIT2, which lacks endogenous p63 expression, enhanced cell growth when implanted into the mouse pancreas in vivo, yet this phenotype was absent under tissue culture conditions ([@bib73]). These findings led us to hypothesize that p63 expression alters how PDA cells communicate with non-neoplastic cells in the tumor stroma. We focused our studies initially on CAFs, which have established roles in PDA pathogenesis ([@bib62]). To this end, we collected conditioned media from 12 human PDA cell lines exhibiting different expression levels of squamous markers (e.g. *TP63* and *KRT5*) ([Figure 1A--C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Of note, MIAPaca2 cells only express the TA isoform of p63 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and lack expression of squamous lineage markers ([@bib73]), and in fact are more representative of a cell type of neuroendocrine origin ([@bib86]). The collected media were then applied to quiescent murine pancreatic stellate cells (PSCs), which are a precursor of CAFs in PDA, and RNA-sequencing (RNA-seq) analysis was performed on the PSC cultures following 96 hr to evaluate the cellular response ([Figure 1D](#fig1){ref-type="fig"}). An unsupervised clustering of the global transcriptional profile of the PSCs revealed three distinct groups ([Figure 1E](#fig1){ref-type="fig"}). Two of the treated PSC cultures clustered closely with the untreated controls, suggesting they remained in a quiescent transcriptional state ([Figure 1E](#fig1){ref-type="fig"}). However, two major groups were found to cluster away from the control PSC cultures and were termed Group 1 and Group 2 ([Figure 1E](#fig1){ref-type="fig"}). Remarkably, the PSCs within the Group 2 cluster were all treated with conditioned media derived from the three PDA cell lines expressing p63 (BxPC3, T3M4, and KLM1; [Figure 1A--B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In addition to this transcriptional phenotype, the conditioned media from p63-expressing lines also led to a stronger induction of PSC proliferation than conditioned media collected from p63-negative lines ([Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}). We next extracted the subset of genes that discriminate the Group 1 and Group 2 clusters of PSC transcriptional responses, identifying 144 and 259 differentially expressed genes, respectively ([Figure 1F](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}). A Gene Set Enrichment Analysis (GSEA) of the Group 2 cluster revealed several top-ranking gene signatures associated with inflammation ([Figure 1G](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Using transcriptome data from our prior study in which we identified iCAFs and myCAFs ([@bib58]), we defined gene signatures associated with these two cell fates ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) and observed a significant enrichment of the iCAF signature within the Group 2 set of PSCs ([Figure 1H](#fig1){ref-type="fig"}). In contrast, the myCAF signature was significantly enriched within Group 1 PSCs ([Figure 1I](#fig1){ref-type="fig"}). RT-qPCR analysis of human PSCs treated with conditioned media from PDA cell lines further validated these findings ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). These findings suggested that a pro-inflammatory secretory phenotype is linked with the acquisition of squamous features in PDA.

![A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in vitro.\
(**A**) Western blot analysis showing p63 expression in a panel of 12 human PDA cell lines. (**B--C**) Bar charts show expression of *TP63* and *KRT5* cell lines shown in (**A**). (**D**) Schematic of experimental workflow for RNA-seq analysis of PSCs following culture in Matrigel with conditioned media from the 12 human PDA cell lines. (**E**) Heatmap representation of unsupervised hierarchical clustering of mouse PSCs based on their global transcriptional profile. Scale bar indicates Pearson correlation coefficient. Control refers to control media, which was DMEM supplemented with 5% FBS. (**F**) Heatmap representation of differentially expressed genes from PSCs in Group 1 and Group 2. Selected genes in each group are listed. Scale bar indicates standardized expression value. (**G**) GSEA plot evaluating Hallmark Inflammatory Response genes based on their expression in Group 2 versus Group 1 cultures. (**H--I**) GSEA plots evaluating the iCAF and myCAF gene signatures in Group 2 versus Group 1 cultures.](elife-53381-fig1){#fig1}

p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro {#s2-2}
---------------------------------------------------------------------------------------------

Based on the correlations described above, we next set out to determine the causality between p63 and the iCAF-inducing secretory phenotype. To this end, we cultured two mouse PSC lines with conditioned media harvested from SUIT2-empty and SUIT2-p63 cells and performed RT-qPCR analysis of iCAF marker genes in the PSC cultures ([Figure 2A](#fig2){ref-type="fig"}). We observed a marked increase in iCAF markers (*Il6*, *Cxcl1*, and *Lif*) and a concomitant reduction of myCAF markers (*Acta2* and *Ctgf*) when the PSCs were cultured in the SUIT2-p63 conditioned media compared to those cultured in SUIT2-empty conditioned media ([Figure 2B--C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A--B](#fig2s1){ref-type="fig"}). In accord with the findings described above, mouse PSCs cultured in the SUIT2-p63 conditioned media were more proliferative when compared to their counterparts cultured in SUIT2-empty conditioned media ([Figure 2---figure supplement 1C--D](#fig2s1){ref-type="fig"}). Similar RT-qPCR experiments using human PSC cultures or using a metastatic mM1 organoid line, which was isolated from the KPC (*Kras^+/LSL-G12D^; Trp53^+/LSL-R172H^; Pdx1-Cre*) mouse model ([@bib10]; [@bib35]), and engineered to ectopically express p63, support the generality of these findings ([Figure 2D--E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1E--F](#fig2s1){ref-type="fig"}).

![p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro.\
(**A**) Schematic of workflow for generating conditioned media from SUIT2-empty and SUIT2-p63 cells and subsequent analysis of PSC cultures. (**B--C**) Bar charts showing RT-qPCR analysis for iCAF markers (*Il6*, *Cxcl1*, *Lif*) following culture of 2 mouse PSC lines in Matrigel for four days with the indicated conditioned media. (**D**) RT-qPCR analysis for the iCAF markers (*IL6*, *CXCL1*, *LIF*) following culture of human PSCs in Matrigel for four days with the indicated conditioned media. (**E**) Mouse mM1 organoids were infected with a p63 cDNA or empty vector control. Bar chart shows RT-qPCR analysis for iCAF markers (*Il6*, *Cxcl1*, *Lif*) following culture of a mouse PSC line in Matrigel for four days in the indicated conditioned medias. (**F**) Schematic of workflow for generating conditioned media from KLM1-Cas9 cells infected with p63 sgRNAs (sg*TP63*\#2 and sg*TP63*\#4) or a control (sgNEG) and subsequent analysis of PSC cultures. (**G--H**) Bar chart showing RT-qPCR analysis for iCAF markers (*Il6*, *Cxcl1*, *Lif*) following culture of mouse PSCs in Matrigel for four days with the indicated conditioned media. (**I**) RT-qPCR analysis for iCAF markers (*IL6*, *CXCL1*, *LIF*) following culture of human PSCs in Matrigel for four days with the indicated conditioned media. For all experiments, control media represents DMEM supplemented with 5% FBS. Mean+ SEM is shown. Results are presented as the mean of three technical replicates and are representative of n = 3 biological replicates. For B-E, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 by Student's t-test and for G-I, \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 by one-way ANOVA with Dunnett's test for multiple comparisons.](elife-53381-fig2){#fig2}

We next performed loss-of-function studies using conditioned media from KLM1-Cas9 cells infected with two independent sgRNAs targeting *TP63* or a control sgRNA ([Figure 2F](#fig2){ref-type="fig"}). Notably, KLM1 is the only p63-positive PDA cell line we have identified which does not exhibit a growth arrest phenotype in vitro following p63 inactivation ([Figure 2---figure supplement 1G--H](#fig2s1){ref-type="fig"}; [@bib73]). Importantly, KLM1 cells harbor a similar transcriptional and epigenomic profile as observed in other p63-expressing PDA cell lines ([Figure 2---figure supplement 1I--K](#fig2s1){ref-type="fig"}). In addition, KLM1 cells also induce a similar iCAF phenotype as seen with other p63-expressing lines ([Figure 1E--F](#fig1){ref-type="fig"}). Hence, this cell line is useful for performing p63 loss-of-function experiments evaluating for secretory phenotypes without the confounding effect of impairing cell fitness.

While conditioned media from KLM1 cells led to a significant induction of iCAF markers and repression of myCAF markers in mouse and human PSCs, this effect was significantly attenuated in p63-knockout KLM1 cells ([Figure 2G--I](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1L--N](#fig2s1){ref-type="fig"}). In addition, the proliferation phenotype of the conditioned media-treated PSCs was also attenuated following p63 inactivation ([Figure 2---figure supplement 1O--P](#fig2s1){ref-type="fig"}). Taken together, these experiments demonstrate the critical role of p63 in regulating the secretory phenotype in squamous-like models of PDA, which promotes the induction of inflammation-associated transcriptional changes in CAFs.

Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor microenvironment in vivo {#s2-3}
-------------------------------------------------------------------------------------------------------------------------------------

We next evaluated the relevance of the p63-induced secretory phenotype in an in vivo model of PDA. For this purpose, we first infected SUIT2-luciferase cells ([@bib73]) with a p63 cDNA or empty vector prior to orthotopic transplantation into the pancreas of NOD-scid gamma (NSG) mice. In accordance with our previous findings ([@bib73]), p63 expression enhanced the growth of SUIT2 cells in vivo, but not in vitro ([Figure 3A--B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A--D](#fig3s1){ref-type="fig"}). Importantly, we validated the in vivo-specific growth advantage caused by ectopic p63 expression in the mM1 organoids following transplantation into the pancreas of C57BL/6 mice ([Figure 3---figure supplement 1E--K](#fig3s1){ref-type="fig"}). Tumors from the SUIT2 xenograft model were harvested and subjected to bulk RNA-seq analysis. Mapping of human and mouse transcripts to their respective genomes allowed us to discriminate the transcriptional changes happening in the human cancer cells from those of non-neoplastic mouse cells comprising the tumor stroma ([Figure 3C](#fig3){ref-type="fig"}).

![Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor microenvironment.\
(**A--I**) SUIT2-empty and SUIT2-p63 PDA cells harboring a luciferase transgene were transplanted into the pancreas of NSG mice. (**A--B**) Quantification of tumor volume (**A**) and images of tumors (**B**) on day 25 post-transplantation. (**C**) Experimental workflow for RNA-seq analysis of bulk tumor tissue. (**D--E**) Heatmap representations of differentially expressed genes that unambiguously map to (**D**) the human genome and therefore are derived from human cancer cells or (**E**) the mouse genome and therefore are derived from mouse stromal cells. Selected genes in each group are listed. Scale bar indicates standardized expression value. (**F**) Ontology analysis of the 500 significantly up-regulated mouse genes using Metascape. GO terms are ranked by their significance (*p* value) and the most significant terms (-log~10~ *p* value \> 15) are highlighted. (**G**) GSEA plot evaluating the iCAF signature in the mouse stromal compartment of SUIT2-p63 versus SUIT2-empty tumors. (**H**) Quantification of flow cytometry analysis of CD45^+^CD11b^+^Ly6G^+^ neutrophils and CD45^+^CD11b^+^F4/80^+^ macrophages from bulk tumor tissues from SUIT2 xenografts. n = 5 mice per group. \*\*\*p\<0.001 by Student's t-test. (**I**) Representative flow cytometry plots from (**H**). (**J--K**) KPC mM1 organoids with a p63 cDNA or empty vector control and transplanted to the pancreas of C57BL6 mice. (**J**) Quantification of flow cytometry analysis of CD45^+^ cells in the tumors. n = 4--5 mice per group. \*\*\*p\<0.001 by Student's t-test. (**K**) Representative flow cytometry plots from (**J**). TCRβ refers to T cell receptor β.](elife-53381-fig3){#fig3}

In the human cancer cell compartment, we identified 633 genes that were significantly upregulated in SUIT2-p63 tumors compared to controls, which largely corresponded to squamous lineage p63 target genes (e.g. *S100A2*, *KRT5)* ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1L](#fig3s1){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}; [@bib5]; [@bib73]). Within the mouse stromal compartment, we identified 500 genes that were significantly upregulated in SUIT2-p63 tumors compared to controls ([Figure 3E](#fig3){ref-type="fig"} and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). An ontology analysis of this set of genes revealed enrichment for inflammatory responses, neutrophil degranulation, and cytokine production as top-ranking gene sets ([Figure 3F](#fig3){ref-type="fig"}). Importantly, the transcriptional signature of iCAFs was significantly more enriched in the mouse stromal compartment of SUIT2-p63 relative to SUIT2-empty tumors ([Figure 3G](#fig3){ref-type="fig"}), which is consistent with our conditioned media experiments ([Figure 2A--D](#fig2){ref-type="fig"}). In this bulk RNA-seq analysis, the transcriptional signature of myCAFs was modestly depleted in SUIT2-p63 tumors, although this was not significant ([Figure 3---figure supplement 1M](#fig3s1){ref-type="fig"}). However, fluorescent activated cell sorting (FACS) of fibroblasts from these two groups of tumors confirmed an increase in iCAF markers and a decrease in myCAF markers in the SUIT2-p63 tumors ([Figure 3---figure supplement 1N--P](#fig3s1){ref-type="fig"}). Flow cytometry analysis confirmed that SUIT2-p63 tumors were more infiltrated with CD45^+^CD11b^+^Ly6G^+^ neutrophils when compared to control tumors, which is a marker of enhanced tissue inflammation ([Figure 3H--I](#fig3){ref-type="fig"}). iCAF induction and neutrophil infiltration were also correlated with pre-existing levels of *TP63* expression in human PDA organoid xenografts models ([Figure 3---figure supplement 1Q--T](#fig3s1){ref-type="fig"}). Moreover, a similar neutrophil infiltration phenotype was observed in the orthotopic mM1-p63 tumors, which also correlated with a decrease in infiltrating CD4- and CD8-positive T cells ([Figure 3J--K](#fig3){ref-type="fig"}). This finding is consistent with prior evidence that tumor-associated neutrophils have an immunosuppressive effect in PDA ([@bib8]; [@bib12]). Finally, plasma concentrations of the murine cytokine IL-6, a marker of systemic inflammation and immunosuppression ([@bib28]; [@bib55]) that is largely produced by iCAFs in PDA ([@bib9]; [@bib23]; [@bib58]), were \~10 fold higher in the mice bearing SUIT2-p63 versus SUIT2-empty tumors ([Figure 3---figure supplement 1U](#fig3s1){ref-type="fig"}). Collectively, these experiments suggest that p63-positive PDA cells induce enhanced stromal inflammation in vivo when compared to p63-negative tumors.

Knockout of p63 in an orthotopic PDA tumor model attenuates stromal inflammation {#s2-4}
--------------------------------------------------------------------------------

We next addressed the impact of p63 inactivation on the tumor microenvironment in vivo. To this end, KLM1-Cas9-luciferase cells were transduced with *TP63* sgRNAs before transplantation into the pancreas of NSG mice ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). By monitoring tumor progression using bioluminescent imaging, we found that p63 inactivation resulted in a significant reduction in tumor growth when compared to control tumors ([Figure 4A--B](#fig4){ref-type="fig"}), which is consistent with in vivo-specific growth enhancement caused by acute p63 expression in SUIT2 and mM1 orthotopic models ([Figure 3A--B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A--K](#fig3s1){ref-type="fig"}). In order to study the impact of p63 inactivation on the tumor microenvironment while controlling for overall tumor burden, we allowed sufficient time for tumors to form in each group before harvesting for analysis when a critical bioluminescent signal was reached. By this endpoint metric, cells transduced with the two independent *TP63* sgRNAs formed tumors with a significantly longer latency versus controls ([Figure 4C](#fig4){ref-type="fig"}). Immunohistochemical analysis for p63 revealed an 'escaper' group (sg*TP63*\#2) that gave rise to p63-positive tumors, suggesting the emergence of p63-positive clones within the pooled population of transplanted cells ([Figure 4D](#fig4){ref-type="fig"}). However, in the second cohort where p63 was inactivated (sg*TP63*\#4), we identified largely p63-negative tumors at endpoint, allowing us to interrogate the tumor microenvironment in a loss of function context ([Figure 4D--E](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

![Knockout of p63 in an orthotopic PDA tumor model attenuates stromal inflammation.\
(**A--E**) KLM1-Cas9 cells expressing a luciferase transgene were infected with two independent p63 or control (sgNEG) sgRNAs and transplanted to the pancreas of NSG mice. (**A**) Quantification of bioluminescence signal. Mean ± SEM is shown. Mice were imaged every four days between day 7 and day 57 post-transplantation. n = 4--5 mice per group. \*p\<0.05 by two-way ANOVA with Sidak's test for multiple comparisons. (**B**) Representative images at day 7 and day 57 post-transplantation from (**A**). (**C**) Table summarizing the median time mice from each group were sacrificed and the tumor volume at endpoint. Endpoint was determined as a bioluminescence signal \>3×10^9^ p/s for each individual mouse. \*\*p*\<*0.01 by log rank (Mantel-Cox) test. (**D**) Quantification of p63 expression as determined by immunohistochemical staining of tumors from the indicated experimental groups. n = 4--5 mice per group. \*\*\*p\<0.001 by one-way ANOVA with Tukey's test for multiple comparisons. (**E**) Representative images from (**D**). Scale bar indicates 50 μm. (**F**) Schematic of experimental workflow and sorting strategy for enriching for human cancer cells, mouse fibroblasts and mouse immune cells and subsequent RNA-seq analysis. (**G--I**) Heatmap representations of differentially expressed genes from the human cancer cell compartment (**G**), mouse fibroblast compartment (**H**) and mouse immune compartment (**I**) and the indicated tumor samples. Selected genes in each group are listed. Scale bar indicates standardized expression value. (**J**) GSEA plot evaluating the iCAF signature in the mouse fibroblast compartment of p63-positive versus control (sgNEG) tumors. (**K**) Ontology analysis of the 463 significantly down-regulated mouse genes from immune compartment using Metascape. GO terms are ranked by their significance (*p* value) and the most significant term (-log~10~ *p* value \> 15) is highlighted. (**L--N**) SUIT2-empty or SUIT2-p63 cells were cultured in isolation or together with mouse PSCs in Matrigel for four days before conditioned media was harvested and used for a trans-well migration assay with freshly isolated mouse neutrophils. (**L**) Schematic of experimental workflow. (**M**) Quantification of trans-well neutrophil migration in the indicated media conditions as determined by confocal imaging. Mean+ SEM is shown. Results are presented as the mean number of invading neutrophils per 10 random fields for each condition and are representative of n = 3 biological replicates. \*\*\*p\<0.001, \*\*p\<0.01 by two-way ANOVA with Sidak's test for multiple comparisons. All significant interactions are shown. (**N**) Representative confocal images from (**M**).](elife-53381-fig4){#fig4}

To achieve this, we FACS-purified human cancer cells, immune cells, and fibroblasts and performed RNA-seq analysis ([Figure 4F--I](#fig4){ref-type="fig"}). Within the cancer cell compartment, we identified 459 genes that were significantly downregulated in the p63-knockout tumors ([Figure 4G](#fig4){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}). As expected, this included *TP63* as well as its downstream target genes, *KRT5*, *KRT6A* and *S100A2* ([Figure 4G](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Within the sorted fibroblast compartment, we identified 396 genes that were significantly downregulated in the p63-knockout tumors, which included a significant suppression of the iCAF gene signature ([Figure 4H--J](#fig4){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}). In contrast, the myCAF gene signature was significantly induced in p63-knockout tumors ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Finally, within the sorted immune cell fraction we identified 463 genes that were significantly down-regulated in the p63-knockout tumors, which was enriched for markers of neutrophils, such as *Ly6g*, *Mpo*, *S100a8*, *S100a9* and *Cxcr2* ([Figure 4I--K](#fig4){ref-type="fig"} and [Supplementary file 4](#supp4){ref-type="supplementary-material"}). We confirmed reduced neutrophil infiltration in the p63 knockout tumors by immunofluorescence staining for LY6G and myeloperoxidase (MPO) ([Figure 4---figure supplement 1E--H](#fig4s1){ref-type="fig"}). Taken together, these findings demonstrate that inactivation of p63 dampens the inflammation-associated transcriptional response present in the CAF and immune compartments of the stroma.

The findings above led us to investigate whether p63-expressing PDA cells can collaborate with CAFs to increase neutrophil infiltration. In order to model this in vitro, we established a co-culture system in which human SUIT2-empty or SUIT2-p63 cells were cultured in Matrigel either alone or in combination with mouse PSCs ([Figure 4L](#fig4){ref-type="fig"}). RT-qPCR analysis for murine-specific transcripts confirmed that SUIT2-p63 cells augmented the iCAF phenotype versus controls in this co-culture system ([Figure 4---figure supplement 1I](#fig4s1){ref-type="fig"}). Of note, this included a marked upregulation of the iCAF gene *Cxcl1*, which encodes an established neutrophil chemoattractant ([@bib53]). We found that the SUIT2-p63/PSC co-cultures released soluble factors that increased the chemotaxis of primary mouse neutrophils and, importantly, this phenotype was enhanced in the SUIT2-p63/PSC co-culture as compared to each cell type individually ([Figure 4M--N](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1J](#fig4s1){ref-type="fig"}). Of note, we found that conditioned media from p63-expressing PDA cells could also promote a modest degree of neutrophil recruitment in the absence of co-cultured PSCs ([Figure 4---figure supplement 1K-M](#fig4s1){ref-type="fig"}). This effect was dependent on CXCL1 ([Figure 4---figure supplement 1K-M](#fig4s1){ref-type="fig"}), which is a p63 target gene in PDA cells (see below). Taken together, these experiments suggest that p63-positive PDA cells possess a secretory phenotype that can promote neutrophil migration, which can be further enhanced by the presence of PSCs/iCAFs.

p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells {#s2-5}
-----------------------------------------------------------------------------------------------------------

We next sought to define a molecular mechanism by which p63 drives a pro-inflammatory secretory phenotype by interrogating the transcriptional changes that occur following ectopic p63 expression in SUIT2 cells ([@bib73]). GSEA comparing SUIT2-p63 to SUIT2-empty cells revealed the activation of a number of inflammation-related pathways as top-ranking gene sets following p63 expression ([Figure 5A--C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Of note, a number of these pathways (e.g. NF-κB and JAK/STAT3 signaling) overlapped with those activated in iCAFs ([@bib9]). Next, we interrogated the transcriptional changes of inflammatory genes that occur following acute p63 inactivation in BxPC3 cells, a human PDA cell line that expresses p63 at high levels ([@bib73]). These analyses identified *IL1A*, *IL1B*, *CXCL1*, *CXCL8*, *CSF2* (*GM-CSF*), *CCL20*, *AREG*, *FJX1*, and *ADORA2B* as the top inflammation-related genes regulated by p63 ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Importantly, an analysis of p63 over-expression and knockout/knockdown RNA-seq datasets performed in nine different human PDA lines or organoids ([@bib73]) revealed that this group of inflammatory genes is regulated by p63 across these different contexts, albeit with a degree of heterogeneity ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) analysis performed in BxPC3 cells revealed that each of these genes is located near a p63-bound enhancer element, suggesting direct transcriptional regulation ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}). Among these p63 targets, *IL1A* and *IL1B* were outliers, as their expression was the most affected by p63 perturbation ([Figure 5D](#fig5){ref-type="fig"}). ChIP-seq analysis revealed a p63-induced super-enhancer located at an intergenic region between the *IL1A* and *IL1B* genes ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1E--H](#fig5s1){ref-type="fig"}). Using CRISPR-interference to target this region for inactivation ([@bib66]), we verified that this group of p63-bound enhancers was responsible for activating *IL1A* and *IL1B* expression ([Figure 5E--F](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1I](#fig5s1){ref-type="fig"}). Taken together, these findings suggest that p63 promotes enhancer-mediated transcriptional activation of genes encoding secreted factors with established roles in promoting inflammation.

![p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells.\
(**A--B**) GSEA plots evaluating the indicated Hallmark gene signatures upon p63 expression in SUIT2 cells. (**C**) Scatter plot shows the mean log~2~ fold change of expressed genes upon p63 expression in SUIT2 cells. Genes with a mean log~2~ fold change \>1 in this dataset and the BxPC3+sg*TP63* dataset ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) that are also found in the gene signatures shown in A and B are highlighted along with the rank. Data are from [@bib73]. (**D**) Heatmap shows gene expression changes in those genes shown in (**C**) in the indicated cell lines following p63 over-expression (left panel) or knockout/knockdown (right panel). Scale bar indicates mean log~2~ fold change versus control. (**E**) ChIP-seq profiles of p63 (top track) and H3K27ac (bottom four tracks) following p63 knockout in BxPC3 cells or overexpression in SUIT2 cells surrounding the *IL1* locus. The H3K27ac regions identified as a super enhancer by ROSE analysis are indicated along with the positions of sgRNAs targeting this enhancer used for experiments shown in (**F**) and (**I**). (**F**) RT-qPCR analysis for *IL1A* and *IL1B* in SUIT2-empty or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated sgRNAs. The positions of the sgRNAs targeting the *IL1* super enhancer are shown in (**E**). (**G--H**) ELISA for IL-1α and IL-1β from conditioned media harvested from KLM1-Cas9 cells infected with the indicated sgRNA (**G**) or from SUIT2-empty and SUIT2-p63 cells (**H**). (**I**) ELISA for IL-1α in SUIT2-empty or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated sgRNAs. (**J--K**) Bar charts showing RT-qPCR analysis for iCAF markers (*Il6*, *Cxcl1*, *Lif*) following culture of clones of two mouse PSC lines from which the IL-1 receptor was clonally knocked out with CRISPR in Matrigel for four days with conditioned media from SUIT2-empty or SUIT2-p63 cells. (**L**) Bar charts showing RT-qPCR analysis for iCAF markers (*Il6*, *Cxcl1*, *Lif*) following culture of PSCs in Matrigel for four days with the conditioned media harvested from cells shown in (**I**). For all experiments, control media represent DMEM supplemented with 5% FBS. Mean+ SEM is shown. For RT-qPCR experiments, results are presented as the mean of three technical replicates and are representative of n = 3 biological replicates and \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 by one-way ANOVA with Dunnett's test for multiple comparisons. For each ELISA experiment, n = 3 biological replicates and \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05 by one-way ANOVA with Tukey's test for multiple comparisons. ns = not significant.](elife-53381-fig5){#fig5}

IL-1α is the key secreted molecule induced by p63 in PDA cells that promotes iCAF induction in vitro {#s2-6}
----------------------------------------------------------------------------------------------------

We focused our subsequent functional experiments on *IL1A* and *IL1B*, which respectively encode interleukin one alpha (IL-1α) and beta (IL-1β) and are important mediators of inflammatory responses, including NF-κB signaling that we found to be upregulated following p63 expression ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}; [@bib20]; [@bib21]). We recently demonstrated a critical role for IL-1 in promoting the induction of iCAFs through the indirect activation of JAK/STAT signaling ([@bib9]). In order to assess whether IL-1α and IL-1β are secreted by p63-expressing PDA cells, we performed enzyme-linked immunosorbent assay (ELISA) experiments for these two proteins on conditioned media following p63 knockout in KLM1 cells. This assay efficiently detected IL-1α, but not IL-1β, in the control setting and the levels of secreted IL-1α were significantly reduced by two independent *TP63* sgRNAs ([Figure 5G](#fig5){ref-type="fig"}). An absence of IL-1β secretion in this context might be due to a lack of inflammasome activation, which is a known requirement for IL-β, but not IL-α secretion ([@bib20]). Consistent with this observation, ectopic expression of p63 in SUIT2 cells led to robust secretion of IL-1α, but not IL-1β, and this effect could be ablated by CRISPR-interference-mediated targeting of the *IL1* super-enhancer ([Figure 5H--I](#fig5){ref-type="fig"}). Taken together, these results indicate that both *IL1A* and *IL1B* are regulated by p63 at the transcriptional level, but only IL-1α is secreted at detectable levels by p63-expressing PDA cells in vitro.

In order to investigate whether p63-driven iCAF induction is conferred via an IL-1-mediated signaling mechanism, we used mouse PSC lines in which the IL-1 receptor (*Il1r1*) was knocked out using CRISPR ([@bib9]) and performed experiments with conditioned media harvested from SUIT2-p63 or SUIT2-empty cells. Consistent with the results above, PSCs infected with the control sgRNA displayed a marked increase in iCAF gene expression following culture in SUIT2-p63 conditioned media ([Figure 5J--K](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1J--K](#fig5s1){ref-type="fig"}). However, this induction was absent in the IL-1 receptor knock out lines ([Figure 5J--K](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1J--K](#fig5s1){ref-type="fig"}). Finally, we confirmed the dependency on IL-1 signaling for p63 driven iCAF induction by performing conditioned media experiments using SUIT2-p63 cells following inactivation of the *IL1* super-enhancer via CRISPR interference ([Figure 5L](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1L](#fig5s1){ref-type="fig"}). These data demonstrate that p63 expressing PDA cells induce an iCAF phenotype via paracrine IL-1α signaling in vitro.

Squamous trans-differentiation of human PDA tumors correlates with increased inflammatory fibroblasts and neutrophil infiltration in patient samples {#s2-7}
----------------------------------------------------------------------------------------------------------------------------------------------------

In order to ascertain whether p63 expression is associated with stromal inflammation changes in human pancreatic cancer patients, we first interrogated three independent datasets that have profiled the transcriptome of bulk tumor tissue ([@bib5]; [@bib11]; [@bib50]). In all three datasets, the expression of *IL1A* was found to be significantly elevated in *TP63*^high^ versus *TP63*^low^ patient samples ([Figure 6A](#fig6){ref-type="fig"}). Of note, it is the ΔN isoform of *TP63* that is overexpressed in squamous-subtype PDA tumors ([@bib5]). We next interrogated single-cell RNA-seq data from 24 human PDA tumors and 11 normal pancreas tissue samples from a recently published study ([@bib61]). This analysis confirmed that *TP63* is aberrantly expressed in the ductal compartment of a subset of patient samples that exhibit high-level expression of squamous marker genes ([Figure 6B--C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}). Importantly, we observed significantly higher expression of inflammatory genes (*CXCL1*, *IL6* and *LIF*) within the fibroblast compartment in *TP63*^high^ versus *TP63*^low^ patients ([Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}). Finally, we performed a multiplex immunofluorescence staining of 12 human PDA tissue samples, which revealed a trend towards increased neutrophil infiltration in p63-positive versus p63-negative PDA samples ([Figure 6E--F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}).

![Squamous trans-differentiation of PDA cells correlates with increased inflammatory fibroblasts and neutrophil infiltration in patient samples.\
(**A**) Quantification of *IL1A* mRNA levels in the indicated studies. Each dot represents one patient sample, and patients were stratified as *TP63*^high^ or *TP63*^low^ as described in [@bib73]. (**B--D**) Single cell RNA-seq data from 24 primary PDA tumor and 11 normal pancreas samples from the study by [@bib61]. (**B**) 24 primary PDA tumor samples ranked by mean *TP63* expression levels across all cell types. Patients were stratified as *TP63*^high^ (n = 4) or *TP63*^low^ (n = 4) as shown. (**C**) Expression of squamous genes in ductal cells from *TP63*^high^ or *TP63*^low^ PDA patient samples from (**B**). (**D**) Expression of inflammatory genes (*IL6*, *CXCL1* and *LIF*) in stellate cells and fibroblast cells from *TP63*^high^ or *TP63*^low^ PDA patient samples from (**B**). Each dot represents a single cell and the four patient samples were pooled for this analysis. (**E--F**) Multiplex immunofluorescent staining of primary pancreatic cancer tumor from the Rapid Autopsy Program. (**E**) Quantification of p63, MPO, αSMA and MUC1 in p63-negative (p63^neg^, n = 6) and p63-positive (p63^pos^, n = 6) samples. (**F**) Representative images of a p63-positive PDA tumor stained with DAPI (blue), MPO (orange), αSMA (white), MUC1 (green), p63 (red), and overlaid (merge). The images were collected from the same tumor area, but over multiple rounds of iterative staining. Scale bar indicates 20 μm. For (**A**), (**C**) and (**D**) \*\*\*p\<0.001, \*\*p\<0.01 by Student's t-test. ns, not significant.](elife-53381-fig6){#fig6}

Discussion {#s3}
==========

Prior studies have revealed PDA to be a heterogeneous disease at the molecular level with respect to both the tumor and stromal compartments ([@bib5]; [@bib11]; [@bib14]; [@bib50]). As both compartments are comprised of cell types that display phenotypic plasticity ([@bib58]; [@bib87]), dissecting the molecular cross-talk between cells that define each patient's tumor remains a formidable challenge. Although prior studies have made correlations between epithelial and stromal transcriptomes in PDA ([@bib49]; [@bib50]; [@bib64]), it remains unclear whether the evolution of these two compartments is dependent on one another.

Here, we have defined a mechanism by which tumor cells gain an ability to reprogram their local microenvironment through the acquisition of p63, which is a master regulator of the squamous subtype of PDA ([@bib31]; [@bib73]). Mechanistically, we have shown that p63 activates a pro-inflammatory secretory phenotype that triggers iCAF induction through an IL-1-dependent signaling mechanism. Importantly, we have verified the correlation between *TP63* and *IL1A* expression in three independent transcriptome studies of human PDA tumors. In addition, in independent studies of primary PDA patient samples, we have shown that squamous trans-differentiation of human pancreatic cancer cells is associated with an enhanced inflammatory CAF phenotype and increased neutrophil infiltration. A recent transcriptome study of human tissue samples also revealed a correlation between squamous-subtype PDA tumors and inflammation-associated changes in the stroma ([@bib19]), which validates that our observations in experimental models are in accord with clinical observations. While the aberrant expression of p63 confers a myriad of tumor cell-intrinsic phenotypes in PDA, such as enhanced motility, invasion, and resistance to cytotoxic chemotherapy ([@bib17]; [@bib73]), our work points to a powerful non cell-autonomous effect of p63 in PDA in promoting stromal inflammation.

We previously demonstrated that IL-1/JAK/STAT signaling is the key pathway responsible for iCAF formation in PDA ([@bib9]). While a basal level of IL-1 is expressed in PDA tumor cells that lack p63 expression ([@bib9]; [@bib76]; [@bib88]), a key finding in our current study is in demonstrating that a striking heterogeneity exists in IL-1 expression in the human disease, with the highest levels being found in p63-expressing squamous-subtype tumors. We account for this observation by demonstrating that a super-enhancer is installed by p63 at the *IL1* locus, which enables a \> 30 fold increase in IL-1α secretion to enhance iCAF formation. One expected outcome of p63-mediated *IL1A* hyperactivation would be a strengthened concentration gradient of IL-1α emanating from tumor cells to promote iCAF induction within the stroma. Whilst this hypothesis is robustly supported in the current study, our in vitro and in vivo studies, together with single cell RNA-seq analysis of PDA patient tumors, suggest that with increasing complexity of the tumor microenvironment, the association of p63 expression in PDA cells with myCAF abundance is more variable. While the abundance and spatial localization of iCAFs and myCAFs are likely regulated by several signaling pathways (e.g. TGF-β), our in vivo findings suggest that the acquisition of p63 expression in the tumor leads to a potent increase in IL-1 secretion to drive iCAF enrichment in the surrounding microenvironment. Interestingly, a recent study identified a critical in vivo role for tumor cell-derived IL-1β in inflammatory CAF activation and immune suppression using murine orthotopic models of PDA ([@bib18]). Mechanistically, the expression of IL-1β in vivo was shown to be driven by toll-like receptor 4 (TLR4) activation and subsequent engagement of the NLRP3 inflammasome. Taken together with our findings, these data suggest that the transcriptional activation of both *IL1A* and *IL1B* may be functionally relevant within the tumor microenvironment of squamous-subtype PDA tumors.

Many of the genes regulated by p63 in PDA cells correspond to those activated by the pro-inflammatory transcription factor NF-κB. Indeed, it has been previously shown that p63 and NF-κB co-occupy a common set of target genes in head and neck squamous cell carcinoma, and this is associated with enhanced inflammation in vivo ([@bib85]). In addition, NF-κB is often constitutively active in most pancreatic cancer tissues and confers resistance to apoptosis ([@bib22]; [@bib79]). In this context, constitutive activation of NF-κB requires an IL-1α-driven feed-forward amplification loop to promote PDA development ([@bib45]; [@bib56]). Maintenance of an inflamed CAF state has also been shown to be dependent on the NF-κB signaling pathway ([@bib9]; [@bib24]). Taken together, these studies raise the possibility that p63 functions as an amplifier of NF-κB transcriptional output to drive enhanced secretion of inflammatory mediators in squamous-subtype PDA tumors. In addition to IL-1α, p63 promotes expression of other pro-inflammatory cytokines that have been implicated in the development and progression of PDA, such as CXCL1 and GM-CSF ([@bib8]; [@bib44]; [@bib65]). Notably, both of these cytokines are also produced by iCAFs ([@bib58]), suggesting that the pro-tumorigenic effects of these factors would be amplified by IL-1α-mediated crosstalk between p63-expressing tumor cells and iCAFs.

An association between squamous cell carcinomas and infiltrating inflammatory cells has been observed previously in other tumor contexts ([@bib3]; [@bib16]; [@bib24]; [@bib25]; [@bib27]; [@bib39]; [@bib83]; [@bib85]). In one study, squamous trans-differentiation in a lung adenocarcinoma mouse model was associated with neutrophil infiltration and other markers of inflammation ([@bib51]). In this context, inflammatory changes were promoted by the squamous lineage transcription factor SOX2 through activation of CXCL5 expression ([@bib51]). It is interesting to note that we also observed a correlation between *TP63* and *SOX2* expression in single cell RNA-seq analysis of tumor ductal cells from PDA patent samples. Taken together with our findings, these results suggest that inflammation is more generally associated with squamous lineage tumors through multiple distinct mechanisms. Interestingly, a major function of the normal squamous epithelium is to serve as a protective barrier to exogenous insults. As such, inflammatory pathways must be tightly regulated and poised for a rapid response in these tissues. Notably, squamous cells of the epidermis are known to express large amounts of IL-1α at steady state ([@bib32]) and *IL1A* is known to be a key p63 target in normal human keratinocytes ([@bib6]). For this reason, amplified inflammation may be an inevitable consequence of tumor trans-differentiation into the squamous lineage in diverse tissue contexts.

Histopathological definitions of PDA are often imprecise and offer limited clinical utility with respect to patient management and treatment selection ([@bib41]). Adenosquamous carcinoma, for example, is defined by those tumors exhibiting \>15% squamous differentiation and is considered an uncommon variant of PDA. Studies that have identified molecular subtypes of PDA using transcriptomic analyses provide the opportunity to define a new molecular taxonomy for pancreatic cancer that is more clinically applicable ([@bib15]). The challenge now is to understand the underlying biology that renders these molecular subtypes phenotypically distinct and to identify robust markers for prospective patient stratification. The findings presented in our study point to p63 as a functional biomarker that identifies a poor prognostic subgroup of PDA patients in which inflammatory pathways are amplified. As such, these patients may benefit from targeted therapies that aim to dampen the inflammatory response. For example, monoclonal antibodies targeting IL-1α or IL-1β have shown promise as potential cancer therapies ([@bib34]; [@bib36]; [@bib68]), and the IL-1 receptor antagonist Anakinra has shown efficacy in pre-clinical models of PDA ([@bib90]). The findings presented in this study suggest that such agents may also show efficacy in appropriately stratified PDA patients.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                       Designation                                            Source or\                                                      Identifiers                                                                                  Additional information
  (species) or resource                                                                      reference                                                                                                                                                    
  ----------------------------------- ------------------------------------------------------ --------------------------------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------
  Genetic reagent (*Mus. musculus*)   NOD.Cg-*Prkdc*^scid^ *Il2rg*^tm1Wjl^/SzJ (NSG)         The Jackson Laboratory                                          Stock \#: 005557, RRID:[IMSR_JAX:005557](https://scicrunch.org/resolver/IMSR_JAX:005557)     

  Genetic reagent (*Mus. musculus*)   C57BL/6J                                               The Jackson Laboratory                                          Stock \#: 000664, RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)     

  Cell line (*Homo sapiens*)          PANC1                                                  ATCC                                                            Cat\# CRL-1469, RRID:[CVCL_0480](https://scicrunch.org/resolver/CVCL_0480)                   

  Cell line (*Homo sapiens*)          PATU8988S                                              DSMZ                                                            Cat\# ACC-204, RRID:[CVCL_1846](https://scicrunch.org/resolver/CVCL_1846)                    

  Cell line (*Homo sapiens*)          SUIT2                                                  JCRB                                                            JCRB1094, RRID:[CVCL_3172](https://scicrunch.org/resolver/CVCL_3172)                         

  Cell line (*Homo sapiens*)          CFPAC1                                                 ATCC                                                            Cat\# CRL-1918, RRID:[CVCL_1119](https://scicrunch.org/resolver/CVCL_1119)                   

  Cell line (*Homo sapiens*)          AsPC1                                                  ATCC                                                            CRL-1682, RRID:[CVCL_0152](https://scicrunch.org/resolver/CVCL_0152)                         

  Cell line (*Homo sapiens*)          PANC0403                                               ATCC                                                            Cat\# CRL-2555, RRID:[CVCL_1636](https://scicrunch.org/resolver/CVCL_1636)                   

  Cell line (*Homo sapiens*)          CAPAN2                                                 ATCC                                                            Cat\# HTB-80, RRID:[CVCL_0026](https://scicrunch.org/resolver/CVCL_0026)                     

  Cell line (*Homo sapiens*)          HPAFII                                                 ATCC                                                            Cat\# CRL-1997, RRID:[CVCL_0313](https://scicrunch.org/resolver/CVCL_0313)                   

  Cell line (*Homo sapiens*)          MIAPaca2                                               ATCC                                                            Cat\# CRL-1420, RRID:[CVCL_0428](https://scicrunch.org/resolver/CVCL_0428)                   

  Cell line (*Homo sapiens*)          BxPC3                                                  ATCC                                                            Cat\# CRL-1687, RRID:[CVCL_0186](https://scicrunch.org/resolver/CVCL_0186)                   

  Cell line (*Homo sapiens*)          T3M4                                                   RCB                                                             Cat\# RCB1021, RRID:[CVCL_4056](https://scicrunch.org/resolver/CVCL_4056)                    

  Cell line (*Homo sapiens*)          KLM1                                                   RCB                                                             Cat\# RCB2138, RRID:[CVCL_5146](https://scicrunch.org/resolver/CVCL_5146)                    

  Cell line (*Homo sapiens*)          Human PSCs                                             PMID:[30366930](https://www.ncbi.nlm.nih.gov/pubmed/30366930)                                                                                                Primary

  Cell line*Mus musculus*             mPSC4; mPSC5                                           PMID:[30366930](https://www.ncbi.nlm.nih.gov/pubmed/30366930)                                                                                                Primary

  Cell line*Mus musculus*             mM1                                                    PMID:[25557080](https://www.ncbi.nlm.nih.gov/pubmed/25557080)                                                                                                Primary

  Antibody                            anti-p63 (rabbit monoclonal)                           Cell Signaling                                                  Cat\# 39692, RRID:[AB_2799159](https://scicrunch.org/resolver/AB_2799159)                    1:1000 (WB)\
                                                                                                                                                                                                                                                          1:500 (IHC)\
                                                                                                                                                                                                                                                          1:500 (IF)

  Antibody                            anti-HSC70 (mouse monoclonal)                          Santa Cruz Biotechnology                                        Cat\# sc-7298, RRID:[AB_627761](https://scicrunch.org/resolver/AB_627761)                    1:5000 (WB)

  Antibody                            anti-ACTB (mouse monoclonal)                           Sigma-Aldrich                                                   Cat\# A3854, RRID:[AB_262011](https://scicrunch.org/resolver/AB_262011)                      1:1000 (WB)

  Antibody                            anti-Cas9 (mouse monoclonal)                           Epigentek                                                       Cat\# A-9000--050, RRID:[AB_2828022](https://scicrunch.org/resolver/AB_2828022)              1:1000 (WB)

  Antibody                            anti-MPO (goat polyclonal)                             R and D Systems                                                 Cat\# AF3667, RRID:[AB_2250866](https://scicrunch.org/resolver/AB_2250866)                   1:200 (IF)

  Antibody                            anti-LY6G (rat monoclonal)                             BD Pharmingen                                                   Cat\# 551459, RRID:[AB_394206](https://scicrunch.org/resolver/AB_394206)                     1:200 (IF)

  Antibody                            anti-MPO (rabbit polyclonal)                           Abcam                                                           Cat\# ab9535, RRID:[AB_307322](https://scicrunch.org/resolver/AB_307322)                     1:200 (IF)

  Antibody                            anti-alpha-SMA (mouse monoclonal)                      Sigma-Aldrich                                                   Cat\# A2547, RRID:[AB_476701](https://scicrunch.org/resolver/AB_476701)                      1:200 (IF)

  Antibody                            anti-Muc1 (Armenian hamster monoclonal)                Abcam                                                           Cat\# ab80952, RRID:[AB_1640314](https://scicrunch.org/resolver/AB_1640314)                  1:200 (IF)

  Antibody                            anti-CD45-PerCP-Cy5-5 (rat monoclonal)                 BioLegend                                                       Cat\# 103132, RRID:[AB_893340](https://scicrunch.org/resolver/AB_893340)                     1:100 (FC)

  Antibody                            anti-PDPN-APC/Cy7 (Syrian hamster monoclonal)          BioLegend                                                       Cat\# 127418, RRID:[AB_2629804](https://scicrunch.org/resolver/AB_2629804)                   1:100 (FC)

  Antibody                            anti-CD326 (EPCAM)-AlexaFluor 647 (mouse monoclonal)   BioLegend                                                       Cat\# 324212, RRID:[AB_756086](https://scicrunch.org/resolver/AB_756086)                     1:100 (FC)

  Antibody                            anti-E-Cadherin-AlexaFluor 647 (rat monoclonal)        BioLegend                                                       Cat\# 147304, RRID:[AB_2563040](https://scicrunch.org/resolver/AB_2563040)                   1:100 (FC)

  Antibody                            anti-CD45-BV510 (rat monoclonal)                       BioLegend                                                       Cat\# 103138, RRID:[AB_2563061](https://scicrunch.org/resolver/AB_2563061)                   1:100 (FC)

  Antibody                            anti-F4/80-BV785 (rat monoclonal)                      BioLegend                                                       Cat\# 123141, RRID:[AB_2563667](https://scicrunch.org/resolver/AB_2563667)                   1:100 (FC)

  Antibody                            anti-Ly6G/Ly6C (Gr-1)-PE (rat monoclonal)              BioLegend                                                       Cat\# 108408, RRID:[AB_313373](https://scicrunch.org/resolver/AB_313373)                     1:100 (FC)

  Antibody                            anti-CD11b-PE-Cy7 (rat monoclonal)                     BioLegend                                                       Cat\# 101216, RRID:[AB_312799](https://scicrunch.org/resolver/AB_312799)                     1:500 (FC)

  Antibody                            anti- CD8a-APC-Cy7 (rat monoclonal)                    BioLegend                                                       Cat\# 100714, RRID:[AB_312753](https://scicrunch.org/resolver/AB_312753)                     1:100 (FC)

  Antibody                            anti-CD4-APC (rat monoclonal)                          BioLegend                                                       Cat\# 100516, RRID:[AB_312719](https://scicrunch.org/resolver/AB_312719)                     1:100 (FC)

  Antibody                            anti-TCRβ-PE-Cy7 (Armenian hamster monoclonal)         BioLegend                                                       Cat\# 109222, RRID:[AB_893625](https://scicrunch.org/resolver/AB_893625)                     1:500 (FC)

  Antibody                            Anti-CD11b-AlexaFluor 488 (rat monoclonal)             BioLegend                                                       Cat\# 101217, RRID:[AB_389305](https://scicrunch.org/resolver/AB_389305)                     1:100 (FC)

  Antibody                            anti-CXCL1 (mouse monoclonal)                          R and D Systems                                                 Cat\# MAB275, RRID:[AB_2292460](https://scicrunch.org/resolver/AB_2292460)                   10 μg/ml

  Antibody                            IgG2B Isotype Control (mouse monoclonal)               R and D Systems                                                 Cat\# MAB004, RRID:[AB_357346](https://scicrunch.org/resolver/AB_357346)                     10 μg/ml

  Recombinant DNA reagent             LentiV-Cas9-puro                                       Addgene                                                         Cat\# 108100                                                                                 

  Recombinant DNA reagent             LRNG vector                                            Addgene                                                         Cat\# 125593                                                                                 

  Recombinant DNA reagent             Lenti-dCas9-KRAB-blast                                 Addgene                                                         Cat\# 89567                                                                                  

  Recombinant DNA reagent             YXP-Cas9-puro                                          This paper                                                                                                                                                   See 'CRISPR-based Targeting' in Materials and methods

  Recombinant DNA reagent             Lenti-luciferase-blast vector                          PMID:[30428345](https://www.ncbi.nlm.nih.gov/pubmed/30428345)                                                                                                

  Recombinant DNA reagent             LentiV-ΔNp63-neo vector                                PMID:[30428345](https://www.ncbi.nlm.nih.gov/pubmed/30428345)                                                                                                

  Peptide, recombinant protein        mouse CXCL1                                            Peprotech                                                       Cat\# 250--11                                                                                

  Peptide, recombinant protein        human CXCL1                                            Peprotech                                                       Cat\# 300--11                                                                                

  Commercial assay or kit             IL-1α ELISA assay                                      R and D Systems                                                 Cat\# DLA50                                                                                  

  Commercial assay or kit             IL-1β ELISA assay                                      R and D Systems                                                 Cat\# DLB50                                                                                  

  Commercial assay or kit             IL-6 ELISA assay                                       R and D Systems                                                 Cat\# M6000B                                                                                 

  Other                               Matrigel                                               Corning                                                         Cat\# 356231                                                                                 

  Other                               3 µm FluoroBlok cell culture insert                    Corning                                                         Cat\# 08-772-141                                                                             

  Software, algorithm                 HISAT2                                                 PMID:[25751142](https://www.ncbi.nlm.nih.gov/pubmed/25751142)   HISAT2, RRID:[SCR_015530](https://scicrunch.org/resolver/SCR_015530)                         

  Software, algorithm                 Cuffdiff                                               PMID:[20436464](https://www.ncbi.nlm.nih.gov/pubmed/20436464)   Cuffdiff, RRID:[SCR_001647](https://scicrunch.org/resolver/SCR_001647)                       

  Software, algorithm                 Morpheus                                               Broad Institute                                                 Morpheus by Broad Institute, RRID:[SCR_017386](https://scicrunch.org/resolver/SCR_017386)    

  Software, algorithm                 Metascape                                              PMID:[30944313](https://www.ncbi.nlm.nih.gov/pubmed/30944313)   Metascape, RRID:[SCR_016620](https://scicrunch.org/resolver/SCR_016620)                      

  Software, algorithm                 GSEA                                                   PMID:[16199517](https://www.ncbi.nlm.nih.gov/pubmed/16199517)   Gene Set Enrichment Analysis, RRID:[SCR_003199](https://scicrunch.org/resolver/SCR_003199)   

  Software, algorithm                 DESeq2                                                 PMID:[25516281](https://www.ncbi.nlm.nih.gov/pubmed/25516281)   DESeq2, RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)                         

  Software, algorithm                 SAMtools 1.4                                           PMID:[19505943](https://www.ncbi.nlm.nih.gov/pubmed/19505943)   SAMTOOLS, RRID:[SCR_002105](https://scicrunch.org/resolver/SCR_002105)                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines and cell culture {#s4-1}
---------------------------

Mouse PSCs and pancreatic organoid lines were previously described ([@bib10]; [@bib58]). Human PSCs were purchased from ScienCell (3830). Mouse PSCs in which the *Il1r1* was knocked out using CRISPR were previously described ([@bib9]). Mouse and human PSCs were cultured in DMEM (10--013-CV; Fisher Scientific) containing 5% FBS. HEK 293 T cells were cultured in DMEM containing 10% FBS. Human PDA cell lines were cultured in RPMI 1640 (Gibco) containing 10% FBS. All cells were cultured with 1% L-glutamine and 1% Penicillin/Streptomycin at 37°C with 5% CO~2~. All cell lines were routinely tested for mycoplasma and were authenticated using STR profiling. For conditioned media experiments, human PDA cell lines or mouse organoids were cultured for 3--4 days in DMEM containing 5% FBS before media were collected and filtered through a 0.45 μm syringe filter to remove debris. Conditioned media were stored at 4°C for no more than 3--4 days or snap frozen and stored at −80°C prior to use.

Lentiviral production and infection {#s4-2}
-----------------------------------

Lentivirus was produced in HEK 293 T cells by transfecting plasmid DNA and packaging plasmids (VSVG and psPAX2) using Polyethylenimine (PEI 25000; Polysciences; Cat\# 23966--1). Media were replaced with target media 6--8 hr following transfection and lentivirus-containing supernatant was subsequently collected every 12 hr for 48 hr prior to filtration through a 0.45 μm filter. For infection of human PDA cells, cell suspensions were mixed with lentiviral-containing supernatant supplemented with polybrene to a final concentration of 4 μg/ml. Cells were plated in tissue culture plates of the appropriate size and lentiviral-containing supernatant was replaced with fresh media after an incubation period of 24 hr. For infection of pancreatic organoids, lentivirus was first concentrated 10x in mouse organoid media ([@bib10]) using Lenti-X concentrator according to the manufacturer's instructions. Organoid cultures were then dissociated into single cells, and spinoculated by centrifugation as described previously ([@bib69]).

CRISPR-based targeting {#s4-3}
----------------------

To generate cell lines in which *TP63* had been stably knocked out, KLM1 cells expressing Cas9 in the LentiV-Cas9-puro vector (addgene \# 108100) were infected in a pooled fashion with control or p63 sgRNAs in the LRNG vector ([@bib69]). Two days post infection with sgRNAs, transduced cells were selected with 1 mg/ml of G418 for five days before they were used for conditioned media experiments or orthotopic transplantations. For GFP-depletion assays, KLM1 and T3M4 cells were infected with sgRNAs as described above but without selection and GFP% was measured on day three (P0) and then every three days post-viral transduction until day 18 (P5). For CRISPR interference at the IL1 enhancer, SUIT2-empty or SUIT2-p63 cells stably expressing catalytically-dead Cas9 fused with a KRAB repression domain in the Lenti-dCas9-KRAB-blast vector (addgene \#89567) were infected in a pooled fashion with sgRNAs targeting IL1 enhancer regions (identified from p63 and H3K27ac ChIP-seq in these lines) in the LRNG vector. Stable cell lines were selected by G418 selection for seven days prior to their use in conditioned media experiments. For doxycycline-inducible CRISPR based targeting of p63 in T3M4 and KLM1 cells, Cas9 from the LentiV-Cas9-puro vector was cloned into the doxycycline-regulated TREtight-cDNA-EFS-rtTA-P2A-Puro vector ([@bib73]) to generate the YXP-Cas9-puro vector. T3M4 and KLM1 cells were infected with the YXP-Cas9-puro vector, selected with 3 μg/ml puromycin to generate stable cell line before infection with sgRNAs targeting *TP63* (sg*TP63*\#4) or a control sgRNA (sgNEG) in LRNG vector. Two days post infection with sgRNAs, transduced cells were selected with 1 mg/ml of G418 for three days and were subsequently treated with doxycycline (1 μg/ml) for 48 hr prior to harvesting RNA and lysate for RNA-seq and western blot analysis, respectively. sgRNA sequences can be found in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

RNA extraction and RT-qPCR analysis {#s4-4}
-----------------------------------

Total RNA was extracted using TRIzol reagent following the manufacturer's instructions. For RNA extraction from cells cultured in Matrigel, cells were lysed by adding TRIzol reagent directly to the Matrigel dome. 200 ng-1μg of total RNA was reverse transcribed using qScript cDNA SuperMix (Quanta bio; 95048--500), followed by RT-qPCR analysis with Power SYBR Green Master Mix (Thermo Fisher Scientific; 4368577) on an ABI 7900HT fast real-time PCR system. Gene expression was normalized to *GAPDH* or *Gapdh* for human and murine gene expression analysis, respectively. RT-qPCR primers used can be found in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

Cell lysate preparation and western blot analysis {#s4-5}
-------------------------------------------------

Cell cultures were collected and 1 million cells were counted by trypan blue exclusion and washed with ice cold PBS. Cells were then resuspended in 100 μl PBS and lysed with 100 μl of 2x Laemmli Sample Buffer supplemented with β-mercaptoethanol by boiling for 30 min. Samples were centrifuged at 4°C for 15 min at 10,000xg and the supernatant was used for western blot analysis with standard SDS-PAGE-based procedures. Primary antibodies used were p63 (Cell Signaling; 39692), HSC70 (Santa Cruz; sc-7298), ACTB (Sigma-Aldrich; A3854) and Cas9 (Epigentek; A-9000--050) and proteins were detected using HRP-conjugated secondary antibodies.

Elisa {#s4-6}
-----

For ELISA of plasma, blood was harvested via cardiac puncture from anesthetized mice at end point and plasma separated by centrifugation. For ELISA of media, conditioned media was harvested as described above. ELISA assays used were IL-1α (DLA50; R and D Systems), IL-1β (DLB50; R and D Systems) and IL-6 (M6000B; R and D Systems).

In Vitro luciferase imaging {#s4-7}
---------------------------

To generate luciferase expressing mouse PSC cultures, cells were infected with a luciferase transgene in a Lenti-luciferase-blast vector ([@bib73]) and stable cell lines were generated by selection with 10 μg/ml blasticidin. Cells were plated at a density of 10,000 cells per 20 μl of Matrigel in each well of a black, clear-bottom, ultra-low attachment 96-well plate (10014--318; CELLSTAR) and 200 μl of conditioned media was added. Cells were imaged following four days of culture using an IVIS Spectrum system (Caliper Life Sciences) six minutes post addition of D-Luciferin (150 μg/ml) to each well. For luciferase-based proliferation assays of SUIT2-p63 cells in vitro, parental SUIT2 cells were first infected with Lenti-luciferase-blast vector and stable SUIT2-luciferase cell lines were generated by selection with 10 μg/ml blasticidin. SUIT2-luciferase cells were then infected with p63 cDNA in LentiV-ΔNp63-neo vector ([@bib73]) or the empty vector as a control. Two days post infection, transduced cells were selected with 1 mg/ml of G418 and on day seven post infection, cells were counted by trypan blue exclusion and seeded at a density of 500 cells per well in 200 μl of media in black 96-well plates (137101; Thermo). Cells were imaged daily as described above.

In Vivo orthotopic transplantations and bioluminescence imaging {#s4-8}
---------------------------------------------------------------

Transplantation of human PDA cells and mouse pancreatic organoid cultures have been described previously ([@bib10]; [@bib73]). For transplantation of human cells, NSG mice were used (NOD.Cg-*Prkdc*^scid^ *Il2rg*^tm1Wjl^/SzJ). For transplantation of mouse cells, C57BL/6J mice were used. For mM1 organoid transplantations, 1 × 10^5^ cells were prepared from organoid cultures as a 45 μL suspension of 50% Matrigel in PBS and injected into the pancreas. For p63 knockout experiments in vivo, KLM1-Cas9 cells were first infected with Lenti-luciferase-blast vector and a stable KLM1-Cas9-luciferase cell line was generated by selection with 10 μg/ml blasticidin. These cells were subsequently infected with control or p63 sgRNAs in LRNG vectors as described above. G418-selected cells were counted by trypan blue exclusion and 5 × 10^4^ viable cells were prepared as a 50 μL suspension of 50% Matrigel in PBS and injected into the pancreas. For in vivo experiments using SUIT2-luciferase cells, these cells were infected with LentiV-ΔNp63-neo vector or the empty vector as a control and two days post infection, transduced cells were selected 1 mg/ml of G418 for five days and on day seven post infection, G418-selected cells were counted by trypan blue exclusion and 2 × 10^4^ viable cells were prepared as a 50 μL suspension of 50% Matrigel in PBS and injected into the pancreas. For bioluminescence imaging, mice were intraperitoneally (IP) injected with D-Luciferin (50 mg/kg) and analyzed using an IVIS Spectrum system (Caliper Life Sciences) ten minutes post IP injection.

Histology and immunohistochemistry {#s4-9}
----------------------------------

Histological analysis and p63 immunohistochemistry (IHC) was performed as previously described ([@bib73]). Primary antibodies used were p63 (Cell Signaling; 39692). Hematoxylin and eosin and Masson's trichrome staining were performed according to standard protocols. Stained sections were scanned with Aperio ScanScope CS and to quantify p63, the percentage of strong positive nuclei was calculated relative to the total number of nuclei with the ImageScope nuclear v9 algorithm.

Immunofluorescence staining {#s4-10}
---------------------------

To stain for myeloperoxidase and Ly6G, paraffin sections were deparaffinized and rehydrated, and antigen retrieval was carried out by boiling slides in Tris EDTA buffer (10 mM Tris Base, 1 mM EDTA, pH 9.0) for 6 min in a pressure cooker. The slides were blocked with 1x blocking buffer (PBS containing 2.5% BSA and 5% goat serum) and Fc receptor blocker (Innovex Biosciences, Richmond, CA), before incubating with anti-myeloperoxidase (1:200, AF3667, R and D) or anti-Ly6G (1:200, \#551459, BD Pharmingen) antibody overnight at 4°C. After two washes in PBS, slides were incubated in the presence of fluorochrome-conjugated secondary antibodies (1:250, Invitrogen) for 1 hr, and counterstained with DAPI (1:200 dilution; Life Technologies). Images were collected at 40x magnification using a Leica SP8 confocal and were analyzed using ImageJ software.

Multiplex immunofluorescence staining of human PDA patient tissues {#s4-11}
------------------------------------------------------------------

Human tissue samples were collected from end stage PDA patients within 3 hr of the patient passing at the Rapid Autopsy Pancreatic Program (RAPP) at the University of Nebraska Medical Center. At autopsy, pathologists identified primary tumor and metastatic sites grossly and samples were collected from tumor, adjacent, and uninvolved tissue. Samples were stored in formalin for rapid paraffin imbedding. 5μm-thick sections were cut and mounted onto charged slides. Immunofluorescent analysis was then performed as follows. The antibody recognizing MPO (Abcam: ab9535) was directly conjugated to fluorescent moieties using Cy5 labeling kits obtained from GE Health (Amersham CyDye kits). Alpha-SMA was purchased directly conjugated to Cy3 (Sigma Aldrich: A2547). Secondary antibodies were used to identify p63 (Cell Signaling: 39692) and Muc1 (Abcam: ab80952). The slides were then deparaffinized and rehydrated using xylene and an alcohol gradient. Antigen retrieval was performed using heated acidic citrate buffer for twenty minutes at low heat in a microwave and the slides were blocked in 1% BSA. The slides were stained with directly labeled antibodies or primary and secondary antibodies as needed. Coverslips were mounted using mounting media with DAPI and allowed to dry for 24 hr before scanning. Following slide scanning, the slides were decoverslipped via inversion in agitated PBS. Once the cover slip was removed the slides were submerged in 3% Triton for ten minutes. Slides were then left in an agitated alkaline H~2~O~2~ solution for fifteen minutes to quench the fluorescent molecule and allow for restaining with a new set of directly labeled antibodies. Three rounds of staining were performed. Slide scanning was performed using a Pannoramic 250 whole slide scanner at x20 (3D Histech). Slides were scanned with the test tissue and a sequential control cut, using consistent exposure for each antibody. Once slides were scanned, they were analyzed using HALO (Indica Labs), a whole slide image analysis software, to determine the exposure of each marker across the tumor microenvironment. Calling a positive 'hit' was based on the average for visual thresholding across five different samples and then applied to all tissue with that antibody stain. These data were used to determine the percentage of cells expressing each marker. A random forest masking algorithm was used to remove autofluorescence associated with tissue damage. Only the tumor, and not the surrounding adjacent normal or necrotic tissue, was analyzed.

Flow cytometry and cell sorting {#s4-12}
-------------------------------

Tumors were processed as previously described ([@bib58]). For sorting of cancer cells, fibroblasts and immune cells from xenografted tumors, cells were stained for 30 min with anti-mouse CD45-PerCP-Cy5-5 (103132; BioLegend), PDPN-APC/Cy7 (127418; BioLegend) and anti-human CD326 (EPCAM)-AlexaFluor 647 (324212; BioLegend), anti-human/mouse E-Cadherin- AlexaFluor 647 (147304; BioLegend) and DAPI for 15 min. Cells were sorted on the FACSAria cell sorter (BD) for DAPI/CD45^−^EPCAM/E-Cadherin^+^ (cancer cells), DAPI/CD45/EPCAM/E-Cadherin^−^PDPN^+^ (fibroblasts) and DAPI^-^CD45^+^ (immune cells) cell populations. Sorted cells were pelleted and resuspended in TRIzol for RNA extraction. For flow cytometric analysis of processed mM1 tumors, antibodies used for analysis of myeloid cells were: anti-mouse CD45-BV510 (103138; BioLegend), F4/80-BV785 (123141; BioLegend), Ly6G/Ly6C (Gr-1)-PE (108408; BioLegend) and CD11b-PE-Cy7 (101216; BioLegend); antibodies used for analysis of T-cells cells were: anti-mouse CD45-BV510 (103138; BioLegend), CD8a-APC-Cy7 (100714; BioLegend), CD4-APC (100516; BioLegend) and TCRβ-PE-Cy7 (109222; BioLegend). For flow cytometric analysis of processed xenografted tumors, antibodies used were anti-mouse CD45-PerCP-Cy5.5 (103132; BioLegend), F4/80-BV785 (123141; BioLegend), Ly6G-Ly6C (Gr-1)-PE (108408; BioLegend) and CD11b-AlexaFluor 488 (101217; BioLegend). Fixable viability dye eFluor450 (eBioscience) was used to differentiate between live and dead cells.

Neutrophil isolation and transwell migration assays {#s4-13}
---------------------------------------------------

Neutrophil isolation was performed as previously described ([@bib2]). Transwell migration assays were performed with conditioned media derived from cell lines ectopically expressing p63 or the empty vector that were cultured alone or in combination with mouse PSCs for five days in Matrigel. 5 × 10^3^ SUIT2 cells and 4 × 10^4^ PSCs were used for the co-cultures. The conditioned media were added to the lower chamber, and primary mouse neutrophils (2.5 × 10^5^) were seeded in 0.5% FBS containing DMEM in the upper chamber of a 3 µm FluoroBlok cell culture insert (08-772-141; Corning) in a 24 well plate. 500 ng of recombinant mouse (250-11; Peprotech) or human (300-11; Peprotech) CXCL1 was added to DMEM with 5% FBS on the day of seeding neutrophils as controls. For experiments with blocking antibodies, 10 μg/ml human CXCL1 (MAB275-100; R and D Systems) or IgG2B isotype control (MAB004; R and D Systems) was added to the neutrophils prior to the addition of the conditioned media. After 24 hr, the FluoroBlok membrane was stained with DAPI (0.05 mg/ml; D1306; Thermo Fisher Scientific) for 5 min, rinsed in water and mounted onto glass slides using mounting media (17985--16; Electron Microscopy Sciences). The number of invading neutrophils was counted in 10 random fields of view using a fluorescence microscope (Leica SP8 Confocal microscope).

RNA-seq library construction {#s4-14}
----------------------------

RNA-seq libraries were constructed using the TruSeq sample Prep Kit V2 (Illumina) according to the manufacturer's instructions. Briefly, 0.5--2 μg of purified RNA was poly-A selected and fragmented with fragmentation enzyme. cDNA was synthesized with Super Script II Reverse Transcriptase (Thermo Fisher; 18064014), followed by end repair, A-tailing and PCR amplification. RNA-seq libraries were single-end sequenced for 50 bp, or for xenograft RNA-seq analysis paired-end sequenced for 150 bp, using an Illumina NextSeq platform (Cold Spring Harbor Genome Center, Woodbury).

RNA-Seq data analysis {#s4-15}
---------------------

Single end 50 bp sequencing reads were mapped to the mm10 or hg38 genomes using HISAT2 with standard parameters ([@bib40]). Structural RNA was masked and, unless stated otherwise, differentially expressed genes were identified using Cuffdiff ([@bib77]). All the following analysis was performed on genes with an RPKM value no less than two in either control or experimental samples. Heat maps of standardized expression values for differentially expressed genes were generated using Morpheus from the Broad Institute (<https://software.broadinstitute.org/morpheus>). To generate ranked gene lists for Pre-ranked GSEA, genes were ranked by their mean log~2~ fold change between the two experimental groups of interest. Gene ontology analysis was performed using Metascape ([@bib89]). For clustering of mouse PSC cultures, the log~2~(RPKM+1) values for each cell line was used to generate a heat map of similarity matrix by Pearson correlation, which was subsequently clustered by Euclidean distance with average linkage using Morpheus. Group 1 and Group 2 cultures were then analyzed using Cuffdiff and those genes with log~2~ fold change \>1 and a FDR value \<0.05 were considered and differentially expressed. For GSEA using the Broad Institutes Hallmark gene sets, mouse gene symbols were converted to their orthologous human symbols and ranked by their average log~2~ fold change in the respective cultures. For RNA-seq analysis of flow sorted cancer cells, fibroblasts and immune cells, those genes with a FDR value \<0.05 when comparing sg*TP63*\#4 versus sgNEG tumors were considered and differentially expressed. For xenograft RNA-seq analysis, paired end 150 bp sequencing reads were mapped to the mm10 or hg38 genomes using HISAT2 with standard parameters. The alignment sam files were converted to bam format using the samtools view command. To disambiguate between the human and mouse reads, Disambiguate ([@bib1]) was run on the bam files, and the unambiguous reads were used for RNA quantification and differential expression analysis using DESeq2 ([@bib46]). For human transcripts, those genes with log~2~ fold change \>1 and a FDR value \<0.1 were considered as differentially expressed. For mouse transcripts, those genes with a FDR value \<0.1 were considered as differentially expressed. To generate a ranked list of mouse genes for GSEA analysis genes the bottom 30% of expressed genes across all groups were removed. The iCAF and myCAF gene signatures were defined as the top 200 up- and down-regulated genes in iCAFs versus myCAFs respectively from the study by [@bib58]. The Squamous-PDA Identity signature has been previously described ([@bib73]). RNA-seq datasets following p63 expression in SUIT2, PATU8988S, HPAFII, AsPC1 and CFPAC1 cells as well as p63 knockout or knockdown in BxPC3 and hF3 cells were from a previous study ([@bib73]).

ChIP-Seq library construction and analysis {#s4-16}
------------------------------------------

ChIP procedures were performed as previously described ([@bib73]). The antibody used for ChIP-seq in this study was H3K27ac (ab4729; abcam). ChIP-seq libraries were constructed using Illumina TruSeq ChIP Sample Prep kit following manufacture's protocol. Briefly, ChIP DNA was end repaired, followed by A-tailing and size selection (300--500 bp) by gel electrophoresis using a 2% gel. 15 PCR cycles were used for final library amplification which was analyzed on a Bioanalyzer using a high sensitivity DNA chip (Agilent). ChIP-seq libraries were single-end sequenced for 50 bp using an Illumina NextSeq platform (Cold Spring Harbor Genome Center, Woodbury). Single end 50 bp sequencing reads were mapped to the hg19 genome using Bowtie2 with default settings ([@bib42]). After removing duplicated mapped reads using SAMtools 1.4 ([@bib43]), MACS 1.4.2 was used to call peaks using input genomic DNA as control ([@bib26]). Only peaks enriched greater than or equal to 10-fold over input samples were used for subsequent analyses. Metagene plots were made by centering H3K27ac ChIP-seq regions on previously defined Squamous Elements ([@bib73]) extended to ±10,000 bp with 100 bp bins. Super enhancer analysis was performed using Rank Ordering of Super-Enhancers (ROSE) as described ([@bib47]; [@bib80]). p63 ChIP-seq in BxPC3 cells and H3K27ac ChIP-seq in hN34, hN35, hT85, PATU8988S, AsPC1, HPAFII, SUIT2, hF3 and BxPC3, as well as H3K27ac in SUIT2 or BxPC3 cells following p63 expression or knockout were from a previous study ([@bib73]).

Single cell RNA-Seq analysis {#s4-17}
----------------------------

Gene expression matrices along with sample and cluster annotations of 24 PDAC and 11 normal pancreas samples from the study by [@bib61] were downloaded from the Chinese National Genomics Data Center (Genome Sequence Archive accession \#CRA001160). Raw digital gene expression counts from the aggregated samples were used to visualize expression of genes of interest between sample types (Tumor vs Normal) and across annotated clusters. Data processing to generate an annotated UMAP projection was handled with the Scanpy v1.4.5 software package ([@bib82]). Briefly, the 35 gene expression matrices were concatenated, normalized, log-transformed and filtered of mitochondrial genes and ribosomal genes prior to principal component analysis, which was restricted to the top 3500 highly variable genes. The top 50 principal components were used to compute the KNN graph and 2D UMAP projection using the default settings. Cells were colored according to cluster assignments from [@bib61].

Statistics {#s4-18}
----------

For graphical representation of data and statistical analysis, GraphPad Prism was used. Statistical analysis was performed as described in the figure legends.

Ethics {#s4-19}
------

All animal procedures and studies were approved by the Cold Spring Harbor Laboratory Animal Care and Use Committee (IACUC protocol number 19-16-8).
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###### Genes corresponding to the Group 1 and Group 2 PSC clusters and the ranked gene list of Group 2 versus Group 1 genes used for GSEA.

Tab-1 (Group 1 genes): List of gene significantly upregulated in the Group 1 PSC cluster versus the Group 2 PSC cluster. Tab-2 (Group 2 genes): List of genes significantly upregulated in the Group 2 PSC cluster versus the Group 1 PSC cluster. Tab-3 (ranked Group 2 vs Group 1): Genes ranked by their mean log~2~ fold change in the Group 2 versus the Group 1 PSC cluster.

###### iCAF and myCAF gene signatures.

Tab-1 (iCAF gene signature): List of 200 mouse genes corresponding to the iCAF gene signature. Tab-2 (myCAF gene signature): List of 200 mouse genes corresponding to the myCAF gene signature.

###### Genes significantly upregulated in the human and mouse compartments of SUIT2-p63 versus SUIT2-empty tumors and ranked gene lists used for GSEA.

Tab-1 (Human cancer cells sig UP): List of 633 human genes significantly upregulated in the human cancer cell compartment of SUIT2-p63 xenografts versus SUIT2-empty xenografts. Tab-2 (Mouse stromal cells sig UP): List of 500 mouse genes significantly upregulated in the mouse stromal cell compartment of SUIT2-p63 xenografts versus SUIT2-empty xenografts. Tab-3 (Human ranked TP63 vs empty): Human genes ranked by their mean log~2~ fold change in the human cancer cell compartment of SUIT2-p63 xenografts versus SUIT2-empty xenografts. Tab-4 (Mouse ranked TP63 vs empty): Mouse genes ranked by their mean log~2~ fold change in the stromal cell compartment of SUIT2-p63 xenografts versus SUIT2-empty xenografts.

###### Genes significantly downregulated in each sorted fraction of p63-negative versus p63-positive KLM1 tumors and gene lists used for GSEA.

Tab-1 (cancer cell sort sig DOWN): List of 459 human genes significantly down regulated in the FACS-purified human cancer cell compartment of p63 knockout versus p63 positive KLM1 xenografts. Tab-2 (fibroblast sort sig DOWN): List of 396 mouse genes significantly down regulated in the FACS-purified mouse fibroblast compartment of p63 knockout versus p63 positive KLM1 xenografts. Tab-3 (immune sort sig DOWN): List of 463 mouse genes significantly down regulated in the FACS-purified mouse immune cell compartment of p63 knockout versus p63 positive KLM1 xenografts. Tab-4 (ranked cancer sgNEG vs sgTP63): Human genes ranked by their mean log~2~ fold change in the FACS-purified human cancer cell compartment of p63 knockout versus p63 positive KLM1 xenografts. Tab-5 (ranked CAFs sgNEG vs sgTP63): Mouse genes ranked by their mean log~2~ fold change in the FACS-purified mouse fibroblast compartment of p63 knockout versus p63 positive KLM1 xenografts.

###### RT-qPCR primer sequences and sgRNA sequences used in this study.

Tab-1 (Mouse RT-qPCR primers): List of mouse RT-qPCR primer sequences used in this study. Tab-2 (Human RT-qPCR primers): List of human RT-qPCR primer sequences used in this study. Tab-3 (sgRNAs): List of sgRNA sequences used in this study.

Data availability {#s7}
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The RNA-seq and ChIP-seq data in this study is available in the Gene Expression Omnibus database <https://www.ncbi.nlm.nih.gov/geo/> with accession number GSE140484.

The following dataset was generated:

SomervilleTDD2020Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammationNCBI Gene Expression OmnibusGSE140484

The following previously published datasets were used:

SomervilleTDDXuYMiyabayashiKTiriacHClearyCRMaia-SilvaDMilazzoJPTuvesonDAVakocCR2018TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal AdenocarcinomaNCBI Gene Expression OmnibusGSE115463

MoffittRAMarayatiRFlateELVolmarKELoezaSGHHoadleyKARashidNUWilliamsLAEatonSCChungAH2015Virtual Microdissection of Pancreatic Ductal Adenocarcinoma Reveals Tumor and Stroma SubtypesNCBI Gene Expression OmnibusGSE71729
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

A major insight from genomic characterization of pancreatic cancers is the recognition of a subtype with squamous differentiation characteristics that is more aggressive clinically and confers an inferior prognosis. This paper provides novel insight in the molecular drivers of these adenosquamous PDA tumors by demonstrating that p63 activates an inflammatory transcriptional program, primarily mediated by upregulation of IL1A and CXCL1, that leads to enrichment of these tumors with neutrophils and cancer associated fibroblasts. The findings add mechanistic specificity to this subtype of pancreas cancer and point toward potential targeted interventions to block these inflammatory signals.

**Decision letter after peer review:**

Thank you for submitting your article \"Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation\" for consideration by *eLife*. Your article has been reviewed by Päivi Ojala as the Senior Editor, a Reviewing Editor, and two reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Trudy Oliver (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. While there is enthusiasm for the work, concerns were raised about novelty, in light of two recent related papers from your groups, and about the functional evidence of the iCAFs and neutrophil infiltrates.

Summary:

This work provides new insights into the phenotypic heterogeneity of pancreatic cancer, indicating that p63, which supports a squamous differentiation program, also stimulates an inflammatory microenvironment. The results in co-culture studies establish the ability of p63 expression in tumor cells to stimulate an iCAF signature by paracrine signaling including direct transcriptional upregulation of IL1A. in vivo data support this model and suggest an p63-iCAF inflammatory program promotes tumor growth, potentially involving neutrophil recruitment. The manuscript is clearly presented and the findings have interest relating to both cancer mechanisms and potential clinical significance. Moreover, the correlation between p63 and IL1A expression in clinical specimens is compelling.

There are also some limitations. The authors imply that the positive role of p63 in the growth of tumors in their models involves the activation of the inflammatory program, this is not demonstrated (see essential revision \#1). There is also a concern about the novelty of the current work, relative to two recent papers from your group on related topics. Sommerville et al., 2018 shows that TP63 is the driver of adenosquamous PDAC. Britti et al., 2019 shows that IL1 from PDAC cells generates iCAFs. We would like you to address why the current paper represents a significant conceptual advance relative to the two earlier stories or simply connects the dots.

Essential revisions:

1\) The study implies that the impact of p63 on pancreatic cancer growth observed in the gain and loss of function studies relates in part to iCAF activation by paracrine signaling. Moreover, the in vitro data presented indicate that IL1A/IL1R1 signaling in the CAF serves as the iCAF switch. Studies to determine the impact of IL1A deletion in tumor cells on in vivo tumor growth, iCAF activation and changes in immune populations would support the significance of the findings. We recognize that such a study (IL1A deletion), if newly initiated, will take some time but would like to hear whether you already have or could generate additional findings on the role of CAFs or neutrophils in vivo. Meta-analysis of the correlation between p63 and the immunological and CAF signatures in public RNAseq datasets for PDA could also strengthen the finding. At a minimum, you should clearly state that the pro-tumor effects observed in vivo could relate to cell autonomous growth regulation rather than any effects on tumor-stroma interplay.

2\) It would be more compelling that neutrophils are impacted by p63 expression in Figure 4 if the authors could stain tumors for LY6G (and/or CD11B/MPO) to better confirm that neutrophils are altered in vivo rather than rely on gene expression signatures.

3\) The main outstanding question in my opinion is whether the neutrophil recruitment phenotype is truly dependent on CAFs, or whether there are tumor-cell-autonomous mechanisms of neutrophil recruitment. Figure 4 speaks to whether CAFs are a critical intermediate to neutrophil recruitment, but this is only done with one cell line. I wonder whether p63 is sufficient to recruit TANs without CAFs in other cell lines? In Figure 4L, it is not clear whether the increase in neutrophil migration with p63 alone is significant, and why unstimulated PSCs seem to promote neutrophil migration on their own? Related to the main question, there may be tumor-cell-autonomous mechanisms of recruiting TANs via p63-induced chemokines that they have identified like IL1A, IL1B, and CXCL1. I would suggest to move the heatmap of gene expression for the cancer cells from Figure S4C to the main Figure 4 to parallel Figure 4G, 4I. In Figure S4C, it is worth noting that CXCL1 is also reduced in tumor cells, which may directly impact neutrophils in a CAF-independent manner.
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Author response

> \[...\] There are also some limitations. The authors imply that the positive role of p63 in the growth of tumors in their models involves the activation of the inflammatory program, this is not demonstrated (see essential revision \#1). There is also a concern about the novelty of the current work, relative to two recent papers from your group on related topics. Sommerville et al., 2018 shows that TP63 is the driver of adenosquamous PDAC. Britti et al., 2019 shows that IL1 from PDAC cells generates iCAFs. We would like you to address why the current paper represents a significant conceptual advance relative to the two earlier stories or simply connects the dots.

Unlike other forms of cancer (e.g. lymphoma), it is only in recent years that a consensus has been reached that molecular subtypes exist in pancreatic cancer (Moffitt et al., 2015; Bailey et al., 2016; The Cancer Genome Atlas Research Network, 2017). From these descriptive studies of clinical samples, a major discovery was made that PDA tumors possessing squamous characteristics are more aggressive and portend an inferior prognosis than classical PDA. It is this novel clinical correlation that motivated our study of driver mechanisms of adenosquamous PDA tumors, as well an intense interest in the PDA field with respect to this novel disease entity. Naturally, an emerging focus in the field is in developing personalized therapeutics that exploit the unique properties of these molecular PDA subtypes.

To date, no prior study has demonstrated that adenosquamous PDA possesses enhanced stromal inflammation relative to classical PDA tumors. Importantly, we support this conclusion using both a detailed analysis of clinical PDA specimens (please see below how we have significantly expanded this analysis in our revised manuscript), as well as experimental results using murine and human PDA cell lines and organoid models, ex vivo and in vivo, employing gain- and loss-of function experiments. While this new discovery builds upon our prior work on p63 and iCAFs, it was not obvious *a priori* that adenosquamous PDA would exhibit enhanced stromal inflammation relative to classical PDA. Since inflammation acts as an 'accelerator' of PDA progression (Guerra et al., 2007), we believe that our current study will represent a significant milestone in demystifying adenosquamous PDA and leads to non-obvious clinical hypotheses for how treatments might be developed to interrupt inflammatory signaling in this subset of patients. For these reasons, we believe the conceptual advance of our study extends beyond simply drawing mechanistic connections between p63, cytokines, and inflammatory cells, but will motivate a different way of thinking about, and potentially treating, a recently identified form of cancer.

> Essential revisions:
>
> 1\) The study implies that the impact of p63 on pancreatic cancer growth observed in the gain and loss of function studies relates in part to iCAF activation by paracrine signaling. Moreover, the in vitro data presented indicate that IL1A/IL1R1 signaling in the CAF serves as the iCAF switch. Studies to determine the impact of IL1A deletion in tumor cells on in vivo tumor growth, iCAF activation and changes in immune populations would support the significance of the findings. We recognize that such a study (IL1A deletion), if newly initiated, will take some time but would like to hear whether you already have or could generate additional findings on the role of CAFs or neutrophils in vivo. Meta-analysis of the correlation between p63 and the immunological and CAF signatures in public RNAseq datasets for PDA could also strengthen the finding. At a minimum, you should clearly state that the pro-tumor effects observed in vivo could relate to cell autonomous growth regulation rather than any effects on tumor-stroma interplay.

In order to address these important points, our revised manuscript includes three new analyses of human PDA specimens or organoids to strengthen the conclusion that adenosquamous tumors are more inflamed than their classical counterparts. First, we have performed multiplex immunofluorescent staining of 12 human PDA tissue samples from a Rapid Autopsy Pancreatic Program, in collaboration with Dr. Tony Hollingsworth at the University of Nebraska, who is now a co-author on our study. Consistent with our prior analysis of bulk tumor tissue samples (Somerville et al., 2018), as well as single cell RNA-seq analysis of human PDA tumors (see below), this analysis revealed a heterogeneous expression pattern of p63 across samples analyzed, enabling us to define p63-negative or p63-positive patient samples (Figure 6E-F and Figure 6---figure supplement 1D). We observed a trend of increased neutrophil infiltration within the p63-positive samples, as indicated by MPO staining (p = 0.06) (Figure 6E-F and Figure 6---figure supplement 1D). Iterative staining of the same samples for αSMA (to mark myofibroblasts) and MUC1 (to mark epithelial tumor cells) did not reveal a difference between the two groups in the number of cells staining positive for these two markers. Taken together with the other findings presented in our manuscript, these observations suggest that adenosquamous PDA tumors exhibit increased neutrophil infiltration that is associated with altered fibroblast function, rather than their absolute number.

Second, we are now including a single cell RNA-seq analysis of 24 human PDA tumors and 11 normal pancreas tissues (extracted from the study by Peng et al., 2019). As shown in Figure 6---figure supplement 1A-B, this analysis identified a subset of tumor ductal (epithelial) cells that aberrantly express *TP63*. Consistent with our prior analysis of bulk tumor tissue samples (Somerville et al., 2018), *TP63* expression was found to be heterogeneous within this patient cohort, enabling us to define *TP63*^high^ and *TP63*^low^ patient samples (Figure 6B). We found that *TP63*^high^ patient samples exhibited significantly higher expression of other squamous marker genes (*KRT5*, *KRT6A*, *S100A2* and *SOX2*) in the ductal epithelial compartment when compared *TP63*^low^ patient samples, consistent with the adenosquamous phenotype (Figure 6C). Importantly, this analysis now allowed us to interrogate gene expression within the fibroblast compartment of these same tumors. Importantly, we observed significantly higher expression of inflammatory genes (e.g. *CXCL1*, *IL6* and *LIF*) in fibroblasts from the *TP63*^high^ group when compared to fibroblasts in *TP63*^low^ tumors (Figure 6D). Unfortunately, this dataset did not contain detectable neutrophil markers in any samples analyzed, suggesting an artifact of sample processing. Nevertheless, this new analysis of clinical specimens at single cell resolution lends strong support for the central conclusion of our study. Of note, we also observed significantly higher, albeit more modest, expression levels of myofibroblast genes (*ACTA2* and *CTGF*) within fibroblasts and stellate cells from the *TP63*^high^ group (Figure 6---figure supplement 6C). The latter observation is in contrast to our findings in vitro and in our NSG xenograft models, which likely reflects the highly complex and dynamic nature of human tumor samples that is not recapitulated in these model systems. For this reason, we have de-emphasized any implication in our study that adenosquamous PDA tumors are depleted of myofibroblast-like cells. Together with the analysis of neutrophils (above, and see below), our revised manuscript emphasizes the acquisition of inflammatory changes within both of these stromal compartments.

Third, we have used early passage organoid cultures of human PDA tumors to analyze the stromal compartment of these models when propagated as an orthotopic xenograft in NSG mice. For this analysis, we compared two human pancreatic tumor organoids classified as either squamous (hF3) or classical (hF27) in our previous study (Tiriac et al., 2018). RNA-seq analysis of the bulk tumor xenograft tissue was performed, followed by mapping of reads to either human or mouse transcriptomes, which confirmed high level *TP63* expression within the hF3 organoid tumor, and the absence of *TP63* expression with the hF27 organoid tumor (Figure 3---figure supplement 1Q). In addition, *TP63* expression in the human tumor compartment was strongly associated with *IL1A* expression and a squamous PDA transcriptional signature (Figure 3---figure supplement 1Q-R). We next interrogated the iCAF signature within the mouse stromal compartments of these two tumors and, consistent with the main conclusion of our study, we observed a significant positive enrichment associated with the hF3 (squamous) tumor versus the hF27 (classical) tumor (Figure 3---figure supplement 1S). Finally, we analyzed the mouse stromal compartments for expression of marker genes highly expressed in neutrophils (*Cxcr2*, *Mpo*, *S100a8* and *S100a9*) and observed high-level expression of these genes within the hF3 stromal compartment, whereas these genes were absent or expressed at very low levels within the hF27 stromal compartment (Figure 3---figure supplement 1T). These observations are in accord with the analysis of primary PDA specimens above, as well as the experimental observations using squamous versus non-squamous PDA cell line xenografts.

It should be emphasized that p63 promotes the expression of several pro-inflammatory cytokines, such as IL-1α and CXCL1. As described below, our revised manuscript provides new evidence that CXCL1 secretion by adenosquamous PDA cells can directly promote neutrophil recruitment (Figure 4---figure supplement 1K-M), which complements results in our original manuscript showing how IL-1α can promote inflammatory changes in fibroblasts/stellate cells. The strong potential for redundancy in this pro-inflammatory response, together with the short time-frame with which we needed to prepare this revision, precluded us from addressing the effects of inactivating IL-1α and/or CXCL1 in PDA xenografts. However, prior studies, including our own, have demonstrated a causal role for IL-1α and CXCL1 in promoting PDA progression in mouse models (Biffi et al., 2019; Li et al., 2018). Additionally, our previous study demonstrated that *Il1a* KO in murine PDA organoids downregulates iCAF formation and impairs tumor growth in vivo (Biffi et al., 2019). We have included additional text in the Discussion to point out how tumor cell autonomous mechanisms also exist downstream of p63 to promote tumor aggressiveness in adenosquamous PDA.

> 2\) It would be more compelling that neutrophils are impacted by p63 expression in Figure 4 if the authors could stain tumors for LY6G (and/or CD11B/MPO) to better confirm that neutrophils are altered in vivo rather than rely on gene expression signatures.

To address this point, we have now performed immunofluorescence staining for LY6G and MPO on the tumor samples harvested from the experiment shown in Figure 4 of the manuscript. As shown in Figure 4---figure supplement 1E-H, p63-negative tumors (sg*TP63*\#4) displayed markedly reduced expression of both markers versus the p63-positive (sgNEG) tumors. These data complement our RNA-seq analysis of the stromal compartment of these tumors and demonstrate that the loss of p63 is associated with a significantly reduced neutrophil infiltration phenotype.

> 3\) The main outstanding question in my opinion is whether the neutrophil recruitment phenotype is truly dependent on CAFs, or whether there are tumor-cell-autonomous mechanisms of neutrophil recruitment. Figure 4 speaks to whether CAFs are a critical intermediate to neutrophil recruitment, but this is only done with one cell line. I wonder whether p63 is sufficient to recruit TANs without CAFs in other cell lines? In Figure 4L, it is not clear whether the increase in neutrophil migration with p63 alone is significant, and why unstimulated PSCs seem to promote neutrophil migration on their own? Related to the main question, there may be tumor-cell-autonomous mechanisms of recruiting TANs via p63-induced chemokines that they have identified like IL1A, IL1B, and CXCL1. I would suggest to move the heatmap of gene expression for the cancer cells from Figure S4C to the main Figure 4 to parallel Figure 4G, 4I. In Figure S4C, it is worth noting that CXCL1 is also reduced in tumor cells, which may directly impact neutrophils in a CAF-independent manner.

In order to investigate more deeply the mechanisms of neutrophil recruitment that are driven by p63 expression in PDA cells independently of fibroblasts, we have now performed gain and loss of function experiments using three independent PDA cell lines (Figure 4---figure supplement 1K-M). For these experiments, conditioned media was harvested from SUIT2 and AsPC1 PDA cells ectopically expressing p63, or from KLM1-Cas9 PDA cells infected with an sgRNA targeting *TP63* (sg*TP63*\#4), or their respective controls. Conditioned media was then used for neutrophil migration assays as described in Figure 4 of the manuscript (without the addition of fibroblasts/stellate cells). As an additional control, we set up these assays in the presence of a CXCL1 blocking antibody or IgG control. Consistent with the reviewer's expectation, we consistently observed an increase in neutrophil migration as a result of ectopic p63 expression in PDA cells without the addition fibroblasts (Figure 4---figure supplement 1K-L). In addition, these effects were largely abolished by the presence of a CXCL1 blocking antibody (Figure 4---figure supplement 1K-L). Similarly, in the loss-of-function experiments, *TP63* knockout resulted in a significant reduction in neutrophil migration versus the control cells (sgNEG), and these effects also appear to be dependent on CXCL1 (Figure 4---figure supplement 1M). These data demonstrate that p63 expression in PDA cells drives tumor cell-autonomous neutrophil recruitment in a CXCL1-dependent manner. We would like to highlight that, in our co-culture experiments shown in Figure 4M of the manuscript, the degree of neutrophil recruitment is markedly increased in the p63-postive PDA cell/stellate cell co-culture context (\~4-fold increase versus control and \~2-fold increase versus p63-positive PDA cells alone). In this original experiment, the increase in neutrophil migration stimulated by p63 alone did not reach statistical significance (analyzed by two-way ANOVA across all 28 possible interactions in this experiment). Additionally, the degree of neutrophil stimulation observed in the unstimulated PSC condition was comparable to unconditioned DMEM media (control), indicating that unstimulated PSCs did not promote neutrophil migration on their own. We apologize for our original presentation of this figure being unclear. To address this, we have moved the CXCL1 positive control conditions to the supplement and have indicated the lack of significant interactions as described. We conclude that there is indeed a tumor cell-autonomous mechanism of neutrophil recruitment driven by p63 expression in PDA cells (via CXLC1 secretion) and that this phenotype is exacerbated by the presence of fibroblast/stellate cells (via IL-1-mediated iCAF induction). To clarify this point, as suggested by the reviewer, we have moved the heatmap of gene expression from the supplement to the main figure and have now labeled *CXCL1* as a gene regulated by p63 in the cancer cell compartment (Figure 4G).
